Skip to content

Clinical study on the efficacy and safety of Yili Shutang formula for stabilizing blood glucose

Clinical study on the efficacy and safety of Yili Shutang formula for stabilizing blood glucose

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063685
Enrollment
Unknown
Registered
2022-09-14
Start date
2022-09-14
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Test group:Yili Shutang formula + dietary guidance
control group:Yili Xinhuo the middle-aged and elderly formula (special formula for clinical trials) + dietary guidance

Sponsors

General Hospital of the Chinese people's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 79 Years

Inclusion criteria

Inclusion criteria: -Patients with type 2 diabetes aged 45-79; -After dietary control or oral antidiabetic drugs, only the maintenance dose is taken, and the variety and dose of drugs need maintain within half a year, while the fasting blood glucose = 6.1 mmol /L or the postprandial blood glucose = 7.8 mmol /L at 2 hours; -Have the habit of drinking milk; -On the basis of full understanding of the trial, the informed consent is voluntarily signed.

Exclusion criteria

Exclusion criteria: -Have type 1 diabetes; -Pregnant or lactating women; -Lactose intolerance, allergy to dairy products or formula ingredients; -Serious complications of major organs such as heart, liver, kidney, or other serious diseases and psychosis; -Taking glucocorticoids or other drugs that affect blood glucose; -Patients with diabetes ketosis, acidosis and infection in the last 3 months of the study; -Other nutritional preparations that may affect the test results are being used; -Participate in other interventional clinical trials within 3 months before screening; -Other circumstances that the study leader considers to be unsuitable for participation.

Design outcomes

Primary

MeasureTime frame
Postprandial blood glucose;

Secondary

MeasureTime frame
glycosylated hemoglobin;24-hour dietary review survey (3 days);Blood routine, blood biochemistry and urine routine;

Countries

China

Contacts

Public ContactYinghua Liu
aqing_930@163.com010-66937785

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026